1. Signaling Pathways
  2. Apoptosis
    Metabolic Enzyme/Protease
  3. Glutathione Peroxidase
  4. Glutathione Peroxidase Isoform
  5. Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitors (63):

Cat. No. Product Name Effect Purity
  • HY-14909
    Bardoxolone
    Inhibitor 99.50%
    Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma.
  • HY-P2818
    Alkaline phosphatase, Bovine intestine
    Inhibitor
    Alkaline phosphatase, Bovine intestine (Apase) is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase, Bovine intestine reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase, Bovine intestine improves survival rate of mice infected with E. coli. Alkaline phosphatase, Bovine intestine improves TNBS-induced colon inflammation.
  • HY-B0182
    Carmofur
    Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
  • HY-179557
    iMQT_020
    Inhibitor 99.45%
    iMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS. iMQT_020 induces apoptosis and ferroptosis. iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer, lung cancer, and colon cancer.
  • HY-P2818F
    Alkaline phosphatase, Human (HEK293)
    Inhibitor
    Alkaline phosphatase (Apase), Human (HEK293) is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase improves survival rate of mice infected with E. coli. Alkaline phosphatase improves TNBS-induced colon inflammation.
  • HY-145581
    Mitiperstat
    Inhibitor 99.12%
    Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO). Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease.
  • HY-114360
    Taurohyodeoxycholic acid
    Inhibitor 99.73%
    Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.
  • HY-111341
    AZD5904
    Inhibitor 99.93%
    AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
  • HY-B0880
    4-Aminobenzohydrazide
    Inhibitor 99.96%
    4-Aminobenzohydrazide (p-Aminobenzohydrazide) is an irreversible myeloperoxidase (MPO) inhibitor (IC50=0.3 μM) that induces oxidative stress burst in neutrophils (ROS IC50=43.6 μM). 4-Aminobenzohydrazide has been used in subacute stroke research.
  • HY-17646
    Verdiperstat
    Inhibitor 99.69%
    Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
  • HY-B0679
    Lubiprostone
    Inhibitor 99.09%
    Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research.
  • HY-100873
    PF-1355
    Inhibitor 99.80%
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
  • HY-P2818E
    Alkaline Phosphatase, Calf intestinal
    Inhibitor
    Alkaline Phosphatase (Apase), Calf intestinal is an alkaline phosphatase from Calf intestinal, and is one of the most active alkaline phosphatases. Alkaline Phosphatase, Calf intestinal is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline Phosphatase, Calf intestinal reduces myeloperoxidase activity and bacterial translocation. Alkaline Phosphatase, Calf intestinal improves survival rate of mice infected with E. coli. Alkaline Phosphatase, Calf intestinal improves TNBS-induced colon inflammation.
  • HY-106228
    HLF1-11
    Inhibitor 99.73%
    HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
  • HY-N11849
    Moracin N
    Inhibitor 99.74%
    Moracin N is a ferroptosis inhibitor that can be isolated from mulberry leaf. Moracin N exerts neuroprotective activity through preventing from oxidative stress.
  • HY-19321
    PF-06282999
    Inhibitor 99.02%
    PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.
  • HY-W013507
    (rac)-Methyl jasmonate
    Inhibitor 99.09%
    (rac)-Methyl jasmonate is the racemate of Methyl jasmonate (HY-135663). Methyl jasmonate is a phytohormone that regulates the defense response of plants under biotic and biotic stress through jasmonate signaling pathway. Methyl jasmonate inhibits the activation of NF-κB signaling pathway. Methyl jasmonate can promote the mitochondrial ROS production, but also scavenges free radicals and reduces the oxidative stress. Methyl jasmonate exhibits anti-inflammatory, antitumor, anticonvulsant, antinociceptive and sedative activities.
  • HY-N0729D
    Linoleic acid,suitable for cell culture
    Inhibitor 99.08%
    Linoleic acid is a critical component of polyunsaturated fatty acids. Linoleic acid reduces GSH-PX and T-SOD activities. Linoleic acid functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid can cause acute oxidative damage to red blood cells, ultimately leading to partial acute anemia. Linoleic acid can be used in the research of skin diseases associated with linoleic acid deficiency.
  • HY-W012352
    2-Hydroxyanthraquinone
    Inhibitor 98.0%
    2-Hydroxyanthraquinone is a product generated by the photochemical oxidation of Anthracene (ANT) (HY-Y0299). 2-Hydroxyanthraquinone induces ferroptosis in cardiomyocytes by depleting GSH and inhibiting GPX4, leading to cardiac developmental malformations. 2-Hydroxyanthraquinone causes damage to the cerebrovascular system and blood-brain barrier in zebrafish by downregulating the Wnt/β-catenin signaling pathway, as well as inducing inflammation and neuronal apoptosis. 2-Hydroxyanthraquinone can be used in studies related to cerebrovascular diseases and cardiotoxicity.
  • HY-125039
    N-Acetyl lysyltyrosylcysteine amide
    Inhibitor 99.81%
    N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation.